A New Hope for Cholesterol Management
A groundbreaking development in the field of medicine has emerged, offering a revolutionary approach to managing high cholesterol. This new medication, which can significantly reduce ‘bad’ cholesterol with just one treatment, has been hailed as a potential game-changer by experts. The therapy is expected to play a crucial role in preventing heart attacks and strokes, particularly among patients who have struggled with traditional treatments.
According to a study published by Eli Lilly, the drug was found to lower cholesterol levels by up to 60 per cent over 18 months. This achievement marks a significant step forward in the fight against cardiovascular diseases, which remain a leading cause of death in the UK.
Challenges with Current Treatments
Over seven million people in the UK are currently on medications designed to lower their cholesterol, such as statins. However, research indicates that up to half of these patients discontinue their medication within a year. The reasons for this include the difficulty of taking a daily pill and the side effects associated with these drugs.
Moreover, many individuals are unaware they have high cholesterol, which can result from poor dietary habits, lack of physical activity, and lifestyle choices such as smoking and excessive alcohol consumption. It’s estimated that six out of ten British adults have dangerously high cholesterol levels, contributing to the annual 170,000 cardiovascular deaths in the country.
The New Gene Therapy Approach
The latest trial involved 35 adults with an inherited form of very high cholesterol or those who had suffered a heart attack at a young age. These participants received the gene therapy drug called VERVE-102, administered through a single infusion. At the highest dose, the therapy reduced LDL, or ‘bad’, cholesterol by up to 62 per cent.
Follow-up assessments after 18 months showed that the lower cholesterol levels were maintained, indicating the long-term effectiveness of the treatment. The results of this phase 1 trial were published in the New England Journal of Medicine and presented at the European Atherosclerosis Society Congress in Athens.
Professor Riyaz Patel, a consultant cardiologist at Barts Health NHS Trust and professor of cardiology at University College London, described the findings as an exciting milestone. He emphasized that the technology is not only effective but also safe, with the potential to offer a “one and done” solution for a common condition.
How the Therapy Works
The new therapy targets a specific gene responsible for the production of bad cholesterol in the liver. By disabling this gene, the treatment aims to reduce the levels of LDL cholesterol in the bloodstream. This innovative approach could provide a more permanent solution compared to traditional medications that require daily administration.
One of the trial participants, 41-year-old Daniel Cullinane, shares his experience. Daniel suffers from genetically high cholesterol, which he discovered after his father passed away at an early age. Despite being prescribed statins, his cholesterol levels remained high. After being referred to the team at Barts, he joined the trial, and his cholesterol levels have since dropped significantly. He has also lost weight and feels much healthier.
Addressing Inequalities in Heart Disease Diagnosis
The breakthrough comes amid growing concerns about disparities in the diagnosis and treatment of heart disease, particularly among women. A recent report highlighted that women are more likely to face delays in diagnosis, which can lead to higher mortality rates.
International scientists, led by the European Society of Cardiology, are advocating for the establishment of dedicated women’s heart centres across Europe to address these inequalities. Dr Julia Grapsa, the report’s lead author, noted that heart disease kills more women than any other condition, yet it remains critically underdiagnosed and undertreated.
A study involving over 1,300 high-risk women in the US found that a six-month programme combining heart health advice with clinical guidelines set by the American Heart Association helped reduce their risk of major heart events. This highlights the importance of tailored approaches to heart disease prevention and management.
